此页面是自动翻译的,不保证翻译的准确性。请参阅 英文版 对于源文本。

The SMARTChip Stroke Study

SMARTChip: A Field Deployable Blood Test for Stroke, Capable of Detecting Brain Ischaemia From the Earliest Stages of Pathology

Stroke is one of the leading causes of death and disability in the UK and currently costs the country £7bn per year. There is an overwhelming need to accurately and rapidly triage patients to allow best use of finite NHS specialist resources for the treatment of stroke.

A simple blood test of substances (the purines) that result from cellular metabolism and are produced in excess when brain cells are starved of oxygen and glucose (as occurs during a stroke) is proposed. The sensors designed by the investigators are used to measure blood purines during a procedure in which blood flow to the brain is reduced to allow surgical interventions on the major arteries that supply the brain. Previous studies by the investigators have shown that as soon as blood flow to the brain is reduced, purines are produced within minutes and are detectable in systemic arterial blood.

The current project will now compare the levels of purines in the blood of stroke patients and controls. The purines will be measured on admission to hospital and 24 hours later. The occurrence and magnitude of a stroke will be determined by an MRI scan given between 24 and 72hrs after admission. This study will establish whether purines are elevated in the blood of stroke patients on admission to hospital compared to healthy controls, and whether this correlates with the size of the stroke and damage to the brain.

研究概览

地位

完全的

条件

详细说明

Stroke patients will be prospectively recruited to the trial on admission to A&E. The patient will undergo normal clinical assessment and treatment for stroke. As soon after admission as possible, a finger-prick blood sample will be taken from the patient and the SMARTChip device will be used to measure the levels of purines in the sample. A medical history of factors relevant to the purine test will also be established. This will include factors such as any medications that might alter purine levels, a prior history of strokes, diabetes, a history (individual or family) of gout, and when they last had food. The patient will also be given a CT head scan as part of their normal treatment.

In sub-set of patients repeated blood samples (once per hour for 6 hours) will be taken to gain information on how purine levels may change in blood following a stroke. In all patients, the blood purines will be re-tested at 24h (±3h).

All patients will be offered the option of an MRI brain scan at 24-72h post-admission and recruitment will continue until 100 patients with MRI measurements have been enrolled. The flexibility in the timing of the scan is to allow scheduling of the scan to fit in with other demands on the MRI. The purpose of the scan is to identify the nature of the cerebrovascular event and quantify any infarction or area of brain bleeding.

Control participants will give blood on 2 occasions 24h apart for a purine test. The purpose of this control is two-fold: 1) to establish the variability of blood purines in healthy controls and 2) to test whether stroke patients have elevated blood purine levels compared to healthy controls.

Healthy volunteer feeding controls will give a baseline blood sample, eat a simple purine rich meal (a meat sandwich) and then give 4 more blood samples at 10, 30, 60 and 120 minutes following the meal. The purpose of this control is to test whether ingestion of a recent meal might alter baseline blood purine measurements.

Main study patients recruited at University Hospitals North Midlands NHS Trust will also be given the option of participating in the Spasticity and Pharmacokinetic sub-studies. Participants taking part in the Spasticity sub-study will provide an additional blood sample to measure biomarkers and will undergo a spasticity assessment at admission, 24h, 72h, 7d and one or two clinic visits between 30-90d post-admission. Participants taking part in the pharmacokinetic sub-group will provide an additional blood sample for measurement of glutamate and other biomarkers at admission, 24h, 72h, 7d and 30-90d post-admission.

研究类型

观察性的

注册 (实际的)

399

联系人和位置

本节提供了进行研究的人员的详细联系信息,以及有关进行该研究的地点的信息。

学习地点

      • Coventry、英国、CV2 2DX
        • University Hospitals Coventry & Warwickshire NHS Trust

参与标准

研究人员寻找符合特定描述的人,称为资格标准。这些标准的一些例子是一个人的一般健康状况或先前的治疗。

资格标准

适合学习的年龄

18年 及以上 (成人、年长者)

接受健康志愿者

是的

有资格学习的性别

全部

取样方法

概率样本

研究人群

Stroke patients: adult patients admitted to the hospital experiencing symptoms of stroke at the time of admission

Controls: adult patients scheduled to undergo non-vascular, non-oncological surgery at the participating hospital sites

Feeding control and spasticity sub-study control participants: Healthy adult members of NHS staff

Traumatic brain injury sub-study: Adult patients with an isolated traumatic brain injury.

描述

Main study

Stroke patients:

Inclusion criteria:

  • Aged 18 years or over
  • Admitted to hospital with suspected stroke, diagnosed by a suitably qualified doctor or nurse using an appropriate clinical assessment (e.g. FAST, NIHSS, WHO criteria)
  • Patient has ongoing symptoms of stroke at the time of enrolment in to the study.

Exclusion criteria:

  • Onset of stroke symptoms >4.5 hours prior to admission or time of onset of symptoms is not known
  • Patient has undergone thrombolysis during current admission (N.B. patients can be enrolled before planned thrombolysis, but not after)
  • Patient's stroke symptoms have resolved completely prior to enrolment in the study
  • The patient, or their consultee if the patient is incapacitated, is unwilling to provide written informed consent

Healthy controls

Inclusion criteria:

  • Aged 18 years and over
  • Scheduled for surgery
  • Available for follow-up

Exclusion criteria:

  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of, or current, gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Feeding Controls sub-study Inclusion criteria

  • Aged 18 years and over
  • Member of NHS staff
  • Willing to eat the study meal provided (sandwich with a meat based filling)

Exclusion criteria

  • Current acute health problems requiring medical review, investigation, or treatment
  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of, or current, gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Spasticity sub-study

Stroke patients Inclusion criteria - Patients with suspected stroke, who have been enrolled on to the main study at UHNM

Exclusion criteria

- Unwilling or unable to provide written informed consent to the spasticity sub-study

Controls Inclusion criteria

  • Aged 18 years and over
  • Member of NHS staff
  • Willing to complete follow-up visits

Exclusion criteria

  • Current acute health problems requiring medical review, investigation, or treatment
  • History of, or evidence of current, cerebrovascular disease, including stroke, transient ischaemic attack, subarachnoid haemorrhage and vascular dementia
  • History of cardiovascular disease, including myocardial infarction, angina or peripheral vascular disease
  • History of gout
  • Currently receiving chemotherapy
  • History of diabetes
  • Unwilling or unable to provide written informed consent

Traumatic brain injury sub-study

Inclusion criteria:

  • Aged 18 years or over
  • Admitted to hospital with Traumatic brain injury, diagnosed by a suitably qualified doctor with CT scan supporting evidence of a bleed and/or clot.

Exclusion criteria:

  • The patient, or their consultee if the patient is incapacitated, is unwilling to provide written informed consent
  • History of Cancer

学习计划

本节提供研究计划的详细信息,包括研究的设计方式和研究的衡量标准。

研究是如何设计的?

设计细节

队列和干预

团体/队列
Stroke patients
Adult stroke patients with suspected stroke will be recruited on admission to hospital. Recruitment will continue until 100 patients have received an MRI at 24h-72h post admission, up to a maximum recruitment threshold of 300 patients.
Control patients
50 adult control patients will be recruited from the non-vascular, non-oncological surgical lists at each participating site
Feeding control participants
15 healthy adult members of NHS staff will be recruited to participate in the feeding control sub-study at University Hospitals Coventry and Warwickshire NHS Trust only.
Spasticity sub-group controls
10 healthy adult members of NHS staff at University Hospitals of North Midlands, will be recruited to take part as spasticity sub-study controls
Traumatic brain injury patients
10 adult patients with an isolated traumatic brain injury at University Hospitals Coventry and Warwickshire NHS Trust and Imperial College Healthcare NHS Trust.

研究衡量的是什么?

主要结果指标

结果测量
大体时间
To determine whether blood purine levels in stroke patients at admission correlate with infarct/ haemorrhage size as determined by MRI or CT scan at 24-72 hours after onset of symptoms
大体时间:24-72h after onset of symptoms
24-72h after onset of symptoms

合作者和调查者

在这里您可以找到参与这项研究的人员和组织。

调查人员

  • 首席研究员:Christopher Imray, PhD、University Hospitals Coventry and Warwickshire NHS Trust

研究记录日期

这些日期跟踪向 ClinicalTrials.gov 提交研究记录和摘要结果的进度。研究记录和报告的结果由国家医学图书馆 (NLM) 审查,以确保它们在发布到公共网站之前符合特定的质量控制标准。

研究主要日期

学习开始 (实际的)

2016年7月13日

初级完成 (实际的)

2022年5月20日

研究完成 (实际的)

2022年5月20日

研究注册日期

首次提交

2016年6月6日

首先提交符合 QC 标准的

2016年6月9日

首次发布 (估计)

2016年6月10日

研究记录更新

最后更新发布 (实际的)

2022年7月12日

上次提交的符合 QC 标准的更新

2022年7月11日

最后验证

2022年7月1日

更多信息

与本研究相关的术语

计划个人参与者数据 (IPD)

计划共享个人参与者数据 (IPD)?

IPD 计划说明

Individual participant data will not be shared

此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.

订阅